Saad S. Kenderian

Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

The Microbiome and Immune Regulation After Transplantation.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.

Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.

Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.

Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.

Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis.

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside.

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies.

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center.

Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies.

Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.

Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes.

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.

A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy.

CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview.

Human chimeric antigen receptor macrophages for cancer immunotherapy.

Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.

Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation.

CRISPR Taking the Front Seat in Immunotherapy.

Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.

A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.

Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.

The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor.

GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.

Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.

CART Cell Toxicities: New Insight into Mechanisms and Management.

CRISPR Takes the Front Seat in CART-Cell Development.

Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.

In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.

Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies.

The prognostic significance of del6q23 in chronic lymphocytic leukemia.

CART cell imaging: Paving the way for success in CART cell therapy.

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.

Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.

Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index.

Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.

Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome.

Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma.

Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?

Challenges of CAR T-cell Therapy in CLL: Lessons Learned.

GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity.

CAR-T Cell Therapy: the Efficacy and Toxicity Balance.